ES2051920T3 - Una composicion farmaceutica y su procedimiento de preparacion. - Google Patents

Una composicion farmaceutica y su procedimiento de preparacion.

Info

Publication number
ES2051920T3
ES2051920T3 ES89109381T ES89109381T ES2051920T3 ES 2051920 T3 ES2051920 T3 ES 2051920T3 ES 89109381 T ES89109381 T ES 89109381T ES 89109381 T ES89109381 T ES 89109381T ES 2051920 T3 ES2051920 T3 ES 2051920T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
preparation procedure
dimetilo
sucinato
fenilmetil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89109381T
Other languages
English (en)
Spanish (es)
Inventor
Masaharu Zeria Pharma Miyajima
Yukiya Zeria Pharmac Yamaguchi
Takao Nissan Chemic Tsunematsu
Toshihisa Nissan Chemical Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Original Assignee
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd, Nissan Chemical Corp filed Critical Zeria Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2051920T3 publication Critical patent/ES2051920T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES89109381T 1988-05-30 1989-05-24 Una composicion farmaceutica y su procedimiento de preparacion. Expired - Lifetime ES2051920T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13226288 1988-05-30
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Publications (1)

Publication Number Publication Date
ES2051920T3 true ES2051920T3 (es) 1994-07-01

Family

ID=26390939

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89109381T Expired - Lifetime ES2051920T3 (es) 1988-05-30 1989-05-24 Una composicion farmaceutica y su procedimiento de preparacion.

Country Status (8)

Country Link
US (1) US4983593A (forum.php)
EP (1) EP0344603B1 (forum.php)
JP (1) JP2528706B2 (forum.php)
CA (1) CA1332152C (forum.php)
DE (1) DE68900356D1 (forum.php)
ES (1) ES2051920T3 (forum.php)
GR (1) GR3003615T3 (forum.php)
NZ (1) NZ229309A (forum.php)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (forum.php) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
ES2184063T3 (es) * 1996-03-18 2003-04-01 Nissan Chemical Ind Ltd Procedimiento de produccion de preparaciones de clorhidrato de efonidipina.
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
IL143375A0 (en) 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
ES2240222T3 (es) * 1999-12-20 2005-10-16 Nicholas J. Kerkhof Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado.
IL149186A0 (en) 1999-12-23 2002-11-10 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
CA2450957A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
DE602005010074D1 (de) 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
US20080096924A1 (en) * 2004-12-17 2008-04-24 Ono Pharmaceutical Co., Ltd. Amorphous Composition
WO2007029660A1 (ja) * 2005-09-06 2007-03-15 Astellas Pharma Inc. 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009038112A1 (ja) 2007-09-21 2009-03-26 Shionogi & Co., Ltd. Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
US9149434B2 (en) 2007-12-03 2015-10-06 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
EP2291079B1 (en) * 2008-05-14 2013-04-24 Merck Sharp & Dohme Corp. Formulations for cathepsin k inhibitors
CN102361870B (zh) 2009-04-03 2015-11-25 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN103153343B (zh) 2010-06-14 2015-02-11 陶氏环球技术有限责任公司 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2654726A4 (en) 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd SOLID DISPERSION FORMULATIONS AND METHODS OF USE
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN113209024A (zh) 2013-12-31 2021-08-06 阿森迪亚制药有限责任公司 疏水性化合物的药物组合物
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
PT3985002T (pt) 2017-03-01 2025-08-29 Achillion Pharmaceuticals Inc Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos
WO2018175648A1 (en) * 2017-03-21 2018-09-27 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
US20230105108A1 (en) 2019-12-19 2023-04-06 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
EP4107166A4 (en) 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810A (ja) 1982-09-10 1984-03-21 Sony Corp 磁性記録体におけるデ−タのマスク及び再生方法
JPS62123117A (ja) 1985-11-22 1987-06-04 Nippon Chemiphar Co Ltd 塩酸ニカルジピン経口用組成物
CN1016063B (zh) * 1986-01-22 1992-04-01 日产化学工业株式会社 二氢吡啶-5-膦酸环亚丙基酯的制备
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
CA1332152C (en) 1994-09-27
NZ229309A (en) 1991-06-25
US4983593A (en) 1991-01-08
GR3003615T3 (forum.php) 1993-03-16
JPH0249728A (ja) 1990-02-20
DE68900356D1 (de) 1991-11-28
EP0344603B1 (en) 1991-10-23
JP2528706B2 (ja) 1996-08-28
EP0344603A1 (en) 1989-12-06

Similar Documents

Publication Publication Date Title
ES2051920T3 (es) Una composicion farmaceutica y su procedimiento de preparacion.
IT8819693A0 (it) Apparecchio atto ad operare, in modo pressoche' istantaneo, la distruzione completa dell'ago di siringhe per iniezione, subito dopo il loro impiego.
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
DE3676670D1 (de) Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
DE69011059D1 (de) Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen.
DK395689D0 (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
NO842290L (no) Fremgangsmaate for fremstilling av preparater inneholdende oralt antidiabetisk aktive stoffer
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ES2067250T5 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
PT101725A (pt) Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem
SE8804628D0 (sv) New compounds
Kastin et al. Inhibition of MSH release in frogs by direct application of L-prolyl-L-leucylglycinamide to the pituitary
ATE67406T1 (de) Nicorandil enthaltende zubereitung zum einspritzen.
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
DE68905613D1 (de) Pharmazeutische zubereitung.
ATE66615T1 (de) Pharmazeutische zubereitung fuer eine parenterale verabreichung, die calcitonin als wirkstoff enthaelt.
KR940005283A (ko) 활성 성분으로 글리센틴을 함유하는 약제
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
NO180269C (no) Analogifremgangsmåte for fremstilling av terapeutisk akive aminoketonderivater

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 344603

Country of ref document: ES